Cargando…
Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2
Despite the huge body of research on osteogenic differentiation and bone tissue engineering, the translation potential of in vitro results still does not match the effort employed. One reason might be that the protocols used for in vitro research have inherent pitfalls. The synthetic glucocorticoid...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124248/ https://www.ncbi.nlm.nih.gov/pubmed/33946412 http://dx.doi.org/10.3390/ijms22094785 |
_version_ | 1783693147835990016 |
---|---|
author | Della Bella, Elena Buetti-Dinh, Antoine Licandro, Ginevra Ahmad, Paras Basoli, Valentina Alini, Mauro Stoddart, Martin J. |
author_facet | Della Bella, Elena Buetti-Dinh, Antoine Licandro, Ginevra Ahmad, Paras Basoli, Valentina Alini, Mauro Stoddart, Martin J. |
author_sort | Della Bella, Elena |
collection | PubMed |
description | Despite the huge body of research on osteogenic differentiation and bone tissue engineering, the translation potential of in vitro results still does not match the effort employed. One reason might be that the protocols used for in vitro research have inherent pitfalls. The synthetic glucocorticoid dexamethasone is commonly used in protocols for trilineage differentiation of human bone marrow mesenchymal stromal cells (hBMSCs). However, in the case of osteogenic commitment, dexamethasone has the main pitfall of inhibiting terminal osteoblast differentiation, and its pro-adipogenic effect is well known. In this work, we aimed to clarify the role of dexamethasone in the osteogenesis of hBMSCs, with a particular focus on off-target differentiation. The results showed that dexamethasone does induce osteogenic differentiation by inhibiting SOX9 expression, but not directly through RUNX2 upregulation as it is commonly thought. Rather, PPARG is concomitantly and strongly upregulated, leading to the formation of adipocyte-like cells within osteogenic cultures. Limiting the exposure to dexamethasone to the first week of differentiation did not affect the mineralization potential. Gene expression levels of RUNX2, SOX9, and PPARG were simulated using approximate Bayesian computation based on a simplified theoretical model, which was able to reproduce the observed experimental trends but with a different range of responses, indicating that other factors should be integrated to fully understand how dexamethasone influences cell fate. In summary, this work provides evidence that current in vitro differentiation protocols based on dexamethasone do not represent a good model, and further research is warranted in this field. |
format | Online Article Text |
id | pubmed-8124248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81242482021-05-17 Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 Della Bella, Elena Buetti-Dinh, Antoine Licandro, Ginevra Ahmad, Paras Basoli, Valentina Alini, Mauro Stoddart, Martin J. Int J Mol Sci Article Despite the huge body of research on osteogenic differentiation and bone tissue engineering, the translation potential of in vitro results still does not match the effort employed. One reason might be that the protocols used for in vitro research have inherent pitfalls. The synthetic glucocorticoid dexamethasone is commonly used in protocols for trilineage differentiation of human bone marrow mesenchymal stromal cells (hBMSCs). However, in the case of osteogenic commitment, dexamethasone has the main pitfall of inhibiting terminal osteoblast differentiation, and its pro-adipogenic effect is well known. In this work, we aimed to clarify the role of dexamethasone in the osteogenesis of hBMSCs, with a particular focus on off-target differentiation. The results showed that dexamethasone does induce osteogenic differentiation by inhibiting SOX9 expression, but not directly through RUNX2 upregulation as it is commonly thought. Rather, PPARG is concomitantly and strongly upregulated, leading to the formation of adipocyte-like cells within osteogenic cultures. Limiting the exposure to dexamethasone to the first week of differentiation did not affect the mineralization potential. Gene expression levels of RUNX2, SOX9, and PPARG were simulated using approximate Bayesian computation based on a simplified theoretical model, which was able to reproduce the observed experimental trends but with a different range of responses, indicating that other factors should be integrated to fully understand how dexamethasone influences cell fate. In summary, this work provides evidence that current in vitro differentiation protocols based on dexamethasone do not represent a good model, and further research is warranted in this field. MDPI 2021-04-30 /pmc/articles/PMC8124248/ /pubmed/33946412 http://dx.doi.org/10.3390/ijms22094785 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Della Bella, Elena Buetti-Dinh, Antoine Licandro, Ginevra Ahmad, Paras Basoli, Valentina Alini, Mauro Stoddart, Martin J. Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title | Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title_full | Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title_fullStr | Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title_full_unstemmed | Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title_short | Dexamethasone Induces Changes in Osteogenic Differentiation of Human Mesenchymal Stromal Cells via SOX9 and PPARG, but Not RUNX2 |
title_sort | dexamethasone induces changes in osteogenic differentiation of human mesenchymal stromal cells via sox9 and pparg, but not runx2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124248/ https://www.ncbi.nlm.nih.gov/pubmed/33946412 http://dx.doi.org/10.3390/ijms22094785 |
work_keys_str_mv | AT dellabellaelena dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT buettidinhantoine dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT licandroginevra dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT ahmadparas dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT basolivalentina dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT alinimauro dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 AT stoddartmartinj dexamethasoneinduceschangesinosteogenicdifferentiationofhumanmesenchymalstromalcellsviasox9andppargbutnotrunx2 |